Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

被引：3
|
作者：
Clark, David A. [1 ,2 ]
机构：
[1] McMaster Univ, Dept Med, Hlth Sci Ctr Rm 3H1E, Hamilton, ON L8S 4K1, Canada
[2] Univ Toronto, Fac Med, Dept Immunol, Toronto, ON, Canada
来源：
INFLAMMOPHARMACOLOGY | 2013年 / 21卷 / 02期
关键词：
Rheumatoid arthritis; Anti-tumor necrosis factor-alpha; Cancer; Meta-analysis; NECROSIS-FACTOR INHIBITORS; MALIGNANCIES; METAANALYSIS; REGISTRY; THERAPY;
D O I：
10.1007/s10787-012-0158-0
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Concern has been raised about an increased risk of lymphoma and skin cancers in patients with rheumatoid arthritis due to administration of anti-TNF-alpha drugs. Meta-analysis of observational data from registries as well as from randomized controlled trials has failed to show a significant increase in the risk of lymphoma when the sample size has been sufficiently large; skin cancer risk may represent a valid concern. Issues relating to interpretation of these data are discussed.
引用
收藏
页码：125 / 127
页数：3
相关论文
共 50 条
  • [41] Acid sphingomyelinase activity is elevated in the serum of rheumatoid arthritis patients, suppressed by anti-TNF-α treatment
    Chung, H. -Y.
    Wickel, J.
    Stuhlmueller, B.
    Kinne, R. W.
    Claus, R. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (06) : S18 - S19
  • [42] Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Voulgari, Paraskevi V.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (05) : 721 - 733
  • [43] Impact of long-term anti-TNF-α treatment on insulin resistance in patients with rheumatoid arthritis
    Seriolo, B.
    Paolino, S.
    Ferrone, C.
    Cutolo, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (01) : 159 - 160
  • [44] Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis
    Gonzalez-Gay, M. A.
    Garcia-Unzueta, M. T.
    De Matias, J. M.
    Gonzalez-Juanatey, C.
    Garcia-Porrua, C.
    Sanchez-Andrade, A.
    Martin, J.
    llorca, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (04) : 373 - 379
  • [45] Reduction of oxidative stress marker levels by anti-TNF-α antibody, infliximab, in patients with rheumatoid arthritis
    Kageyama, Y.
    Takahashi, M.
    Ichikawa, T.
    Torikai, E.
    Nagano, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (01) : 73 - 80
  • [46] Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-α
    Corrado, Addolorata
    Colia, Ripalta
    Rotondo, Cinzia
    Sanpaolo, Eliana
    Cantatore, Francesco Paolo
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (12) : 2197 - 2205
  • [47] Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?
    Mulleman, Denis
    Ducourau, Emilie
    Paintaud, Gilles
    Ternant, David
    Watier, Herve
    Goupille, Philippe
    JOINT BONE SPINE, 2012, 79 (02) : 109 - 112
  • [48] Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody:: a prospective open-label pilot study
    Lange, U
    Teichmann, J
    Müller-Ladner, U
    Strunk, J
    RHEUMATOLOGY, 2005, 44 (12) : 1546 - 1548
  • [49] Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-α treatment response in rheumatoid arthritis
    Christian Dejaco
    Christina Duftner
    Werner Klotz
    Michael Schirmer
    Manfred Herold
    Rheumatology International, 2010, 30 : 451 - 454
  • [50] Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis
    Rueda-Gotor, Javier
    Gonzalez-Gay, Miguel A.
    Blanco Alonso, Ricardo
    Gonzalez-Vela, Carmen
    Lopez-Obregon, Cristina
    Gonzalez-Lopez, Marcos A.
    JOINT BONE SPINE, 2012, 79 (05) : 510 - 513
12345